• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Distinct impact of glycation towards the aggregation and toxicity of murine and human amyloid-β?
  Eunju Nam,Jiyeon Han,Sunhee Choi,Mi Hee Lim Chem. Commun., 2021,57, 7637-7640
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

Professional Introduction to N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine (CAS No. 1494639-71-2)

N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine, a compound with the chemical identifier CAS No. 1494639-71-2, represents a significant advancement in the realm of pharmaceutical chemistry and medicinal research. This pyrimidine derivative has garnered considerable attention due to its unique structural properties and potential applications in the development of novel therapeutic agents.

The molecular structure of N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine consists of a pyrimidine core substituted with a butyl group at the 4-amino position, a methyl group at the 2-position, and a chlorine atom at the 6-position. This specific arrangement of functional groups imparts distinct chemical reactivity and biological activity, making it a valuable scaffold for further derivatization and optimization.

In recent years, there has been a surge in research focused on developing small molecule inhibitors targeting various biological pathways relevant to human diseases. Pyrimidine derivatives, in particular, have emerged as a privileged class of compounds due to their ability to interact with biological targets such as enzymes and receptors with high specificity. The presence of both hydrophobic and hydrophilic moieties in N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine enhances its solubility and bioavailability, which are critical factors for drug-like properties.

One of the most compelling aspects of this compound is its potential application in the treatment of neurological disorders. Studies have demonstrated that pyrimidine-based molecules can modulate neurotransmitter systems, making them candidates for drugs targeting conditions such as Alzheimer's disease, Parkinson's disease, and epilepsy. The chloro substituent at the 6-position of N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine is particularly noteworthy, as it can serve as a handle for further chemical modifications aimed at enhancing binding affinity and selectivity.

Moreover, the butyl groups at the amino positions contribute to the compound's lipophilicity, which is often desirable for crossing biological membranes. This feature is particularly relevant in drug design, where membrane permeability is a key determinant of pharmacokinetic behavior. Recent computational studies have suggested that N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine may exhibit favorable interactions with specific amino acid residues in target proteins, providing a strong foundation for structure-based drug design.

The synthesis of N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, such as transition metal-catalyzed cross-coupling reactions and microwave-assisted synthesis, have been employed to streamline the process and improve efficiency. These techniques not only enhance scalability but also reduce the environmental impact of production.

In vitro pharmacological studies have begun to uncover the potential therapeutic benefits of N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine. Initial experiments have shown that it can inhibit the activity of certain enzymes implicated in inflammation and oxidative stress, which are hallmark features of various chronic diseases. Additionally, preliminary data suggest that this compound may exhibit neuroprotective effects by modulating calcium signaling pathways in neurons.

The development of novel drug candidates is an iterative process that involves extensive characterization at multiple levels. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography (HPLC) are crucial for confirming molecular structure and assessing purity. These methods provide detailed insights into the compound's chemical properties, which are essential for understanding its behavior in biological systems.

The future prospects for N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-amine are promising, with ongoing research aimed at expanding its therapeutic applications. Collaborative efforts between academic researchers and industry scientists are likely to yield innovative derivatives with improved pharmacological profiles. As our understanding of disease mechanisms continues to evolve, compounds like this one will play an increasingly important role in precision medicine approaches tailored to individual patient needs.

In conclusion, N,N-Dibutyl-6-chloro-2-methylpyrimidin-4-am ine (CAS No. 1494639 -71 -2) stands out as a versatile and promising compound with significant potential in pharmaceutical research. Its unique structural features and favorable physicochemical properties make it an attractive candidate for further development into novel therapeutic agents targeting various human diseases. As research progresses, this compound is poised to contribute valuable insights into drug discovery and development strategies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)